interleukin-2 receptors modulator(Affymax/Aventis)

N/A

Report date: 2025/03/20 20:00:06
NME

Base Information

Drug Nameinterleukin-2 receptors modulator(Affymax/Aventis)
Drug Alias NameIL-2 receptors modulator(Affymax/Aventis)
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionInterleukin-2 receptor antagonists
TargetsInterleukin-2 receptor
Therapy Area/IndicationsAutoimmune DiseasesCardiovascular DiseasesArthritis, Rheumatoid
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesAffymax NV
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesAventis PharmaAffymax NVHoechst Marion Roussel Ltd
Active IndicationsN/A
Inactive IndicationsAutoimmune DiseasesCardiovascular DiseasesArthritis, Rheumatoid

Other Information

ATC CodeN/A
Related LinksN/A